Logo Coronavir.org

Coronavir.org

Site de veille et d'information sur le nouveau coronavirus SARS-COV-2 et la maladie associée COVID-19

Actualités et recherches en cours

Many countries have approved the use of Pfizer-BioNTech's mRNA BNT162b2 vaccine for children aged 12–17 years,1 and there are safety and efficacy trials underway in children younger than 12 years.2 Published research examining parents’ hesitancy to vaccinate their children against COVID-19 has been based on data from samples selected using non-probability-based selection methods, which are not likely to be representative.3...

Increased hospitalisation risk with SARS-CoV-2 delta (B.1.617.2) variant infection compared with alpha (B.1.1.7) variant infection in unvaccinated people was reported by Katherine Twohig and colleagues in the UK (hazard ratio [HR] 2·32 [95% CI 1·29–4·16])1 and Peter Bager and colleagues in Denmark (3·01 [2·02–4·50]).2 To corroborate these results in the USA, as well as to examine risk of intensive care unit (ICU) admission or death, we analysed a...

Prior to the availability of a COVID-19 vaccine and when case numbers were low, our longitudinal survey with Australian adults showed that 85·8% (3741 of 4362) were willing to be vaccinated in April, 2020, and 89·8% (1144 of 1274) in July, 2020.1,2 Younger adults perceived themselves to be at less risk of infection and were less willing to receive a vaccine....

The WHO global tuberculosis report 2021 was released in October, and for the first time in 10 years described a global increase in deaths from tuberculosis. Sanjeet Bagcchi reports....

Remdesivir remains a controversial treatment for COVID-19.1 ACTT-1 was an international study funded by the US National Institutes of Health that showed reduced time to recovery with remdesivir (its updated primary endpoint) and improvement on an eight-point ordinal scale (the original primary endpoint).2 Mostly based on this trial, the US Food and Drug Administration (FDA) approved the emergency use of remdesivir for patients with COVID-19.3 Thi...

Researchers found that protection against SARS-CoV-2 infection declined for all three vaccine types available to most Americans, with overall vaccine protection declining from 87·9% in February to 48·1% by October, 2021. The study analysed infection by vaccination status among 780 225 US veterans. The decline was greatest for the Janssen (Johnson & Johnson) vaccine, with protection falling from 86·4% in March to 13% in September. The decline for ...

For many years, the Dutch writer Cees Nooteboom's name has been mentioned in the press as a candidate for the Nobel Prize of Literature. Nooteboom's latest poetry book, translated into English by David Colmer as Leaving—A Poem from the Time of the Virus has many themes and influences that are common to Nooteboom's work, such as gardening (533), trauma (Self-portrait of Another), ancient Greek philosophy (Monk's Eye), and death (The Foxes Come at ...

Law Enforcement Officers (LEOs), firefighters, and other first responders are at increased risk of SARS-CoV-2 infection compared to healthcare personnel but have relatively low COVID-19 vaccine uptake. Resistance to COVID-19 vaccine mandates among first responders has the potential to disrupt essential public services and threaten public health and safety. Using data from the HEROES-RECOVER prospective cohorts, we report on the increased illness...

Background SARS-CoV-2 vaccination might impact on clinical progression of cases with breakthrough COVID-19 disease. Objective to evaluate the impact of SARS-CoV-2 vaccination on disease progression in COVID-19 hospitalized patient Methods and Findings Two-hundred eighty-four consecutive COVID-19 hospitalized patients, including 50 vaccinated cases entered the study. Compared to unvaccinated cases, vaccinated patients were older, exhibited more c...

Previous vaccine efficacy (VE) studies have estimated neutralizing and binding antibody concentrations that correlate with protection from symptomatic infection; how these estimates compare to those generated in response to SARS-CoV-2 infection is unclear. Here, we assessed quantitative neutralizing and binding antibody concentrations using standardized SARS-CoV-2 assays on 3,067 serum specimens collected during July 27, 2020-August 27, 2020 fro...

Important : Le contenu diffusé sur Coronavir.org ne doit jamais remplacer les conseils d'un médecin ou des autorités de santé locales.